TW201431561A - The enteric capsule with oil coating - Google Patents

Abstract

In this enteric capsule with oil coating, powdered or garrulous contents meant to fill the capsule is mixed with a dose of ester containing sesaminol triglucosides or coixenolide. With the feature that emulsification arises while ester containing Sesaminol Triglucosides or coixenolide is integrated with the bile in human body, so that the activity of pharmacological molecules can be prevented, the pharmacological molecules of the contents is able to be coated by ester, forming carriers which are the ester oil film protecting the pharmacological activity of small molecules and ensuring that they can be transported to the small intestine. In this way, the capsule will prevent the pharmacological molecules of the contests from being decomposed by gastric acid when the capsule passes through it. Before entering the small intestine, with the emulsification brought about by the combination of ester oil film and bile, the pharmacological molecules of the contents can remain active for the optimum pharmacological activity after their entrance into the small intestine, decomposition, emulsification, and transportation into the blood. The absorptivity of the capsule will be enhanced when it is consumed. As a consequence, chances that the consumption of the capsule with pharmacological molecules causes the irritation of stomach will be effectively reduced, and stomach health will be protected.

Description

Oil film coated intestinal solvent type

The invention relates to an oil film coated enteric solvent type, in particular to a drug molecule dosage form which can be activated into the intestinal digestive tract to decompose and emulsify to achieve an optimal state and absorption rate and to reduce the oil film coating intestine which stimulates the stomach and protects the stomach health. Solvent type.

According to the general prescription, there is a pharmaceutical or health food dosage form in the capsule, which is convenient to carry and easy to take. However, after being orally administered to the stomach of the human body, the stomach acid will quickly dissolve the capsule. In order to dissolve the contents of the contents, the capsule type which is conventionally used, in addition to easily irritating the stomach and injuring the stomach, is more likely to be cracked and destroyed by gastric acid and has a long disintegration time, and the absorption efficiency is not optimal. The state of the disease, but can not be completely released into the digestive tract decomposition, so the absorption rate in the intestine will be reduced, resulting in the proportion of ingredients reaching the small intestine absorbed by the body is not high and it is difficult to fully ensure its activity and absorption effect, it is necessary to improve .

In view of this, the present inventors have developed the present invention by virtue of long-term research and integration of relevant industries, and have been designed with many years of experience, and have been explored and tested for sample testing.

The main object of the present invention is to provide an oil film-coated enteric solvent type which is coated with a drug substance having a dosage form of powdered or granular form using an ester substance of sesame lignan (sesol) or decyl ester. The carrier is formed to protect the small molecule drug from being transported to the small intestine of the ester oil film layer, so that the dosage form can prevent the drug activity of the content from being decomposed by gastric acid into the small intestine before the small intestine and the bile by the gastric acid disintegrating the shell layer. After the combination of emulsification, the content from the contents can be kept in an active state and instantly released to the small intestine for effective absorption, so that the drug molecules of the content can enter the intestinal digestive tract, decompose and emulsifie, and then output into the human blood to achieve an optimal state and enhance absorption. effect Rate, reduce the stimulation of the stomach and protect the health of the stomach, in order to provide a good way to take gastric ulcer disease and achieve the absorption rate of the enhanced dosage form.

10‧‧‧ dosage form

11‧‧‧ shell

12‧‧‧ contents

121‧‧‧ drug molecules

122‧‧‧ester oil film

13‧‧‧ core space

The first picture is the production flow chart of this creation.

Figure 2 is a combined perspective view of the creation.

Figure 3 is a combined sectional view of the creation.

Figure 4 is an enlarged cross-sectional view of the drug molecule of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT A preferred embodiment will be described in detail with reference to the following detailed description of the present invention. Referring to Figures 1 to 4, the present invention provides an oil film coated enteric solvent type (10) which is dosed. An ester containing sesame lignan (sesol) or decyl ester, and a content of the powder or granule substance (12, which can be used as a medicine or a health food) which is prepared to be filled in the dosage form (10) is miscible with the ester substance. By using an ester substance containing sesame lignan (sesol) or an ester of an oxime ester to bind to human bile and emulsifying and retaining the content of the drug (12), the drug molecule of the content (12) (121) being coated with an ester substance to form a carrier for protecting the small molecule drug from being transported to the ester oil film layer (122) of the small intestine, and the content (12) described above may also be set as a triplet and a polysaccharide. The three-type and polysaccharide system is extracted from sesame lignan and burdock or by sesamin and decyl ester by supercritical carbon dioxide. The dosage form (10) may also be a capsule and comprises a shell layer (11) and a core space (13). ), filling the above content (12) in the core space (13), and by containing the zhi The esterified oil film layer (122) formed by the ester of lignan (sesol) or oxime ester coated with the drug molecule (121) is emulsified in combination with human bile for inclusion in the core space (13). The property (12) maintains the characteristics of activity. When the contents (12, such as three-posts and polysaccharides) of the capsule type (10) of the present invention are orally administered to the stomach of the human body, the drug substance is coated with the ester substance. (121) The ester oil film layer (122) constituting the ester oil film protective film, and the drug substance (121) which can reach the content (12) after the drug form (10) is disintegrated by the gastric acid (11) Its active state and has a multiplier effect without being The gastric acid is decomposed, and the ester oil film layer (122) before entering the small intestine is emulsified in combination with the bile, and the content (12) is preserved from the contents thereof and instantly released to the small intestine for effective absorption, so that the drug molecule (121) enters the small intestine for digestion. After decomposing and emulsification, it is exported to the human body to achieve the optimal state and improve the efficiency of absorption, and improve the content of the capsule (12) which is susceptible to decomposition by gastric acid lysis, thereby reducing the stimulation of the stomach and the dosage form. To protect the health of the stomach, to provide a good way to take gastric ulcer disease, and to achieve the absorption rate of the drug dosage form (equivalent to the injected dose).

In summary, it is known that the present invention can be widely utilized by related industries, and is extremely progressive and novel, and the present invention has not been disclosed before the application, has complied with the provisions of the Patent Law, and has filed an invention patent application according to law. I would like to ask the bureau to observe and benefit from patents.

The above is only the preferred embodiment of the present invention, and the scope of the present invention is not limited thereto; that is, the equivalent changes and modifications made by the scope of the present invention should still belong to the present invention. Within the scope of the patent.

10‧‧‧ dosage form

11‧‧‧ shell

12‧‧‧ contents

121‧‧‧ drug molecules

122‧‧‧ester oil film

13‧‧‧ core space

Claims (4)

An oil film coated enteric solvent type, which is obtained by taking a dose of an ester containing sesame lignan (sesol) or oxime ester, and mixing a content of a powder or a granular substance in a dosage form with the ester substance. The ester substance containing sesame lignan (sesol) or oxime ester can be emulsified by binding to human bile and retaining the characteristics of the drug molecule activity of the content, so that the drug molecule of the content is coated with the ester substance. The carrier is used for protecting the activity of the small molecule drug to the ester oil film layer of the small intestine, so that when the dosage form passes through the stomach acid, the content in the dosage form can maintain its active state and have a multiplying effect without being decomposed by gastric acid to enter the small intestine for digestion. The road is decomposed and emulsified and exported to the human blood, thereby achieving the optimum state of the edible dosage form and the absorption rate of the enhanced dosage form. The oil film according to claim 1 is coated with an enteric solvent type, wherein the dosage form is a capsule and comprises a shell layer and a core space filled with the above contents. The oil film according to claim 1 is coated with an enteric solvent type, wherein the content is a medicine or a health food which is a powder or a particulate matter. The oil film according to claim 3 is coated with an enteric solvent type, wherein the content system can be set as three kinds of polysaccharides and polysaccharides, and the three types of polysaccharides and polysaccharides are composed of sesame lignan and burdock or by sesamin and decyl ester. Supercritical carbon dioxide is extracted.